Related Experiment Video
Updated: Aug 21, 2026
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
A Novel Oncogene and Therapeutic Target, Germ Cell-Specific Gene 2 (GSG2), Plays Complex Roles in Promoting Malignant
Zihui Niu1, Shiqiang Hou1, Zhiming Sun1
1Department of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, 239000, China.
Background:
Despite decades of advancements in glioma therapy, challenges such as drug resistance, tumor recurrence, and heterogeneous treatment responses persist, underscoring the need for novel molecular targets. Currently, little is known about the vital roles of GSG2 involved in glioma. Hence, this is the first article studying the roles of GSG2 in glioma in combination with bulk RNA-Sequencing (RNA-Seq) data mining and experimental validations.
Methods:
For bioinformatics analysis, glioma bulk RNA-seq data were mined to reveal the RNA expression levels, prognostic values, and related pathways of GSG2 in glioma. As for the experiments, Western blot and IHC staining validated the expression of GSG2 in glioma cells and tissues. CCK-8, Transwell, and wound healing assays were performed to determine the proliferative, invasive, and migratory phenotypes of glioma cells. Moreover, the GSG2 stable knockdown cell lines and the xenograft assay in nude mice were also conducted to assess the effects of GSG2 on related pathway genes in vivo and in vitro.
Results:
Glioma bulk RNA-seq data mining showed that the GSG2 mRNA expression levels were highly expressed in glioma tissues, as verified by Western blot and IHC staining. Moreover, it is also significantly linked with a worse OS prognosis (P-values < 0.05). Cox regression analysis demonstrated that the prognostic value of GSG2 in glioma was independent after adjusting for these nine potential confounding factors, and GSEA revealed six GSG2-related pathways in glioma (p-values < 0.05). Cellular functional experiments showed that GSG2 knockdown might potently inhibit the proliferative, invasive, and migratory phenotypes in glioma cells (p-values < 0.05). Besides, it could also regulate the PI3K/AKT/mTOR, EMT, glycolysis, and cell cycle-related pathway genes in vivo and in vitro (p-values < 0.05).
Discussion:
Bioinformatics analysis showed the mRNA expression levels and prognostic values of GSG2 in glioma tissues. Further in vivo and in vitro experiments validated the high expression of GSG2 in glioma and its potential cellular functions. All of these indicated the complex roles of the GSG2 gene in glioma.
Conclusion:
GSG2 could serve as an oncogene and play complex roles in glioma, making it a candidate prognostic and therapeutic target for these patients.
Insights
GSG2 is highly expressed in glioma and linked to poor prognosis. Inhibiting GSG2 may suppress tumor growth and offers a potential therapeutic target for glioma patients.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Genetics
Background:
- Glioma therapy faces challenges like drug resistance and recurrence.
- Novel molecular targets are crucial for improving glioma treatment outcomes.
- The role of GSG2 in glioma remains largely unexplored.
Purpose of the Study:
- To investigate the expression, prognostic value, and functional roles of GSG2 in glioma.
- To explore GSG2's potential as a therapeutic target in glioma.
Main Methods:
- Bioinformatic analysis of glioma bulk RNA-sequencing (RNA-Seq) data.
- Experimental validation using Western blot, IHC, CCK-8, Transwell, and wound healing assays.
- In vivo and in vitro studies including GSG2 knockdown and xenograft assays.
Main Results:
- GSG2 mRNA expression is elevated in glioma tissues and associated with worse overall survival (OS).
- GSG2 knockdown inhibited glioma cell proliferation, invasion, and migration.
- GSG2 influences key pathways including PI3K/AKT/mTOR, EMT, and glycolysis.
Conclusions:
- GSG2 is highly expressed in glioma and acts as an independent prognostic factor.
- GSG2 plays complex oncogenic roles in glioma progression.
- GSG2 represents a promising prognostic and therapeutic target for glioma.
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:38Mitogens and the Cell Cycle
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...